The HARMONY Executive Committee, Steering Committee, Work Package Leads, Research Projects Leads, Project Management Team and Communication Team extends its gratitude to all those who have contributed to the success of HARMONY over the past year.
It is with continued support from our Partners and Associated Members that we have been able to make progress in our goals to enable better and faster treatment for patients with blood cancer.
Since our launch in January 2017, HARMONY has continued to evolve and gain momentum. By the end of 2019, we will have identified 45 000 medical records of patients with blood cancer to be included in the HARMONY Big Data Platform, making it one of the largest databases of its kind. HARMONY researchers have been using the Big Data Platform to generate important evidence that is moving us closer to our goal of improving and accelerating treatment for patients with blood cancer.
Achievements by end of 2019
There are a number of exciting new research projects, scientific communications and meetings lined up for next year.
New to HARMONY? Here are three videos to get you up to speed
Why should you become a part of HARMONY?
If your organization has data from patients with Hematologic Malignancies to share, please contact us and learn how to become a HARMONY Associated Member – there is a lot to gain! You will:
Established in January 2017, HARMONY is a public–private European Network of Excellence for Big Data in hematology. Our mission is to unlock and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders, with the goal to harness and mine Big Data to speed up the development of improved treatments for patients and more effective treatment strategies. HARMONY currently has 53 Partners and 37 Associated Members from 22 countries.
HARMONY is funded through the Innovative Medicines Initiative (IMI), Europe's largest public–private initiative which aims to speed up the development of better and safer medicines for patients. HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. Read more
Receive the latest news. Click here to subscribe!